Clearside raises $16 million B round

Ophthalmic play Clearside Biomedical Inc. (Alpharetta, Ga.) raised $16 million in a series B round led by new investor RusnanoMedInvest. Existing investors Hatteras Venture Partners; Santen Pharmaceuticals Co. Ltd. (Tokyo:4536); Mountain Group Capital; and Georgia Research Alliance Venture Fund also participated.

By year end, Clearside plans to start Phase II testing of lead compound CLS-1001 to treat macular edema associated with non-infectious uveitis; and CLS-1003 to treat macular edema associated with retinal vein occlusion (RVO). ...